Why the study?
Do CMR mapping techniques (T1, extracellular volume, T2) show differences between patients with sarcoidosis with preserved LVEF and healthy controls?
Do CMR mapping techniques (T1, extracellular volume, T2) show differences between patients with sarcoidosis with preserved LVEF and healthy controls?
CMR mapping techniques (T1, ECV, T2) show elevated values in sarcoidosis patients with preserved LVEF compared to healthy controls, suggesting potential utility for early diagnosis.
Answers are grounded in this paper and cite their sources.
May support early detection of subclinical cardiac involvement in sarcoidosis; hypothesis-generating and requires prospective validation before clinical use.
Patients with sarcoidosis demonstrate higher T1, extracellular volume, and T2 values compared with healthy controls, with most significant differences for native T1 and T2. While promising, the clinical significance of the newer mapping techniques with respect to early diagnosis and therapy of CS will have to be determined in future studies.
No takes yet. Share an insight, caveat, or question.
Greulich et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: